{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:58:23Z","timestamp":1777870703058,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T00:00:00Z","timestamp":1243382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T00:00:00Z","timestamp":1243382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infusionsther Transfusionsmed"],"abstract":"<jats:p>Objective: The effects of hapten inhibition with dextran 1 (molecular weight: 1,000 D, Promit\u00ae), which is in use since 1982 for the prevention of severe dextran-induced anaphylactic reactions (DIAR) caused by immune complexes, were studied. Design: Spontaneous reports to the manufacturer and to the WHO database INTDIS regarding adverse reactions to clinical dextran after preinjection of dextran 1 and to dextran 1 alone were collected from 1983 to 1992. During this period a total of 5.1 million doses of dextran 1 were sold in 15 countries. Interventions: Analysis of pre- and post-reaction titers of dextran-reactive antibodies (DRA) was made in most Scandinavian reports. Results: The incidence of severe DIAR (grades III-V) to clinical dextran after the prophylactic use of hapten inhibition was approximately 1\/200,000 patients receiving dextran 1. In Sweden, where reporting of severe adverse drug reactions is mandatory, the incidence was approximately 1\/70,000, indicating a 35-fold reduction. Only 2 fatal reactions were reported, an incidence of 1\/2.5 million doses, indicating a 90-fold reduction. Both these occurred in patients with extremely high titers of DRA. Side effects to dextran 1, mostly mild, were reported in approximately 1 case per 100,000 doses. These side effects were not antibody mediated. Conclusions: The above findings, together with other recent safety profile data, suggest that dextran with hapten inhibition has possibly become the safest plasma substitute in current clinical practice.<\/jats:p>","DOI":"10.1159\/000222845","type":"journal-article","created":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T09:34:18Z","timestamp":1243416858000},"page":"206-210","source":"Crossref","is-referenced-by-count":3,"title":["Safety of Dextran in Relation to Other Colloids \u2013 Ten Years Experience with Hapten Inhibition"],"prefix":"10.1159","author":[{"given":"Karl-G\u00f6sta","family":"Ljungstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,5,27]]},"container-title":["Infusionstherapie und Transfusionsmedizin \/ Infusion Therapy and Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/222845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000222845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:33:55Z","timestamp":1777566835000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000222845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000222845","archive":["Portico"],"relation":{},"ISSN":["1019-8466","1423-0089"],"issn-type":[{"value":"1019-8466","type":"print"},{"value":"1423-0089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,27]]}}}